![]() | |
Names | |
---|---|
IUPAC name
(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid
| |
Other names
| |
Identifiers | |
3D model (
JSmol)
|
|
PubChem
CID
|
|
| |
| |
Properties | |
C51H68N2O10 | |
Molar mass | 869.109 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
BIIB131 (also known as SMTP-7 or TMS-007) is a prothrombolytic small-molecule drug developed by Biogen for acute ischemic stroke. [1] [2] [3]
![]() | |
Names | |
---|---|
IUPAC name
(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid
| |
Other names
| |
Identifiers | |
3D model (
JSmol)
|
|
PubChem
CID
|
|
| |
| |
Properties | |
C51H68N2O10 | |
Molar mass | 869.109 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
BIIB131 (also known as SMTP-7 or TMS-007) is a prothrombolytic small-molecule drug developed by Biogen for acute ischemic stroke. [1] [2] [3]